Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

June 23, 2017

Primary Completion Date

March 28, 2022

Study Completion Date

November 2, 2023

Conditions
Metastatic Colorectal Adenocarcinoma
Interventions
DRUG

Trastuzumab

Given intravenously (into the vein; IV)

DRUG

Tucatinib

Given orally

Trial Locations (56)

1200

Cliniques Universitaires Saint Luc, Brussels

2650

Universitair Ziekenhuis Antwerpen, Edegem

3000

UZ Leuven campus Gasthuisberg, Leuven

10065

Memorial Sloan Kettering Cancer Center, New York

14203

Roswell Park Cancer Institute, Buffalo

15212

Allegheny General Hospital, Pittsburgh

20007

Lombardi Cancer Center / Georgetown University Medical Center, Washington D.C.

20141

Instituto Europeo di Oncologia, Milan

20162

Niguarda Ca' Granda Hospital, Milan

21000

Center Georges Francois Leclerc, Dijon

25030

Hospitalier Jean Minjoz, Besançon

27710

Duke University Medical Center, Durham

28007

Hospital General Universitario Gregorio Maranon, Madrid

30322

Winship Cancer Institute / Emory University School of Medicine, Atlanta

33705

Florida Cancer Specialists - North Region, St. Petersburg

33901

Florida Cancer Specialists - South Region, Fort Myers

35249

University of Alabama at Birmingham, Birmingham

37203

Tennessee Oncology-Nashville/Sarah Cannon Research Institute, Nashville

37232

Vanderbilt University Medical Center, Nashville

44106

Case Western Reserve University / University Hospitals Cleveland Medical Center, Cleveland

46010

Hospital Clinico Universitario de Valencia, Valencia

46202

Indiana University Simon Cancer Center, Indianapolis

48201

Karmanos Cancer Institute / Wayne State University, Detroit

52242

University of Iowa Hospitals and Clinics, Iowa City

53215

Aurora Research Institute Cancer Center, Milwaukee

55905

Mayo Clinic Rochester, Rochester

56126

Azienda Ospedaliero-Universitaria Pisana - Ospedale S. Chiara, Pisa

66205

University of Kansas Cancer Center, Westwood

69373

Centre Leon Berard - Centre regional de lutte contre le cancer Rhone-Alpes, Lyon

75012

Hopital Saint-Antoine, Paris

75246

Texas Oncology - Baylor Sammons Cancer Center, Dallas

75702

Texas Oncology - Tyler, Tyler

78240

Texas Oncology - San Antonio Medical Center, San Antonio

78503

Texas Oncology - McAllen, McAllen

79410

Joe Arrington Cancer Research and Treatment Center, Lubbock

80012

Rocky Mountain Cancer Centers - Aurora, Aurora

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

85054

Mayo Clinic Arizona, Phoenix

85234

Banner MD Anderson Cancer Center, Gilbert

89169

Comprehensive Cancer Centers of Nevada, Las Vegas

90033

Keck Medical Center / University of Southern California, Los Angeles

90048

Cedars Sinai Medical Center / Samuel Oschin Comprehensive Cancer Institute, Los Angeles

90813

Pacific Shores Medical Group, Long Beach

92300

Hôpital Franco-Britannique - Fondation Cognacq-Jay, Levallois-Perret

94304

Stanford University School of Medicine, Palo Alto

95403

Saint Joseph Heritage Medical Group, Santa Rosa

97227

Northwest Cancer Specialists, P.C., Portland

98201

Providence Regional Medical Center Everett, Everett

60637-1470

University of Chicago Medical Center, Chicago

02114

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institute, Boston

97239-3098

Oregon Health and Science University, Portland

77702-1449

Texas Oncology - Beaumont, Beaumont

98109-1023

Seattle Cancer Care Alliance / University of Washington, Seattle

08035

Hospital Universitario Vall d'Hebron, Barcelona

08907

Institut Catala d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet), L'Hospitalet de Llobregat

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Academic and Community Cancer Research United

OTHER

lead

Seagen Inc.

INDUSTRY

NCT03043313 - Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer | Biotech Hunter | Biotech Hunter